469 related articles for article (PubMed ID: 21930999)
21. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
[TBL] [Abstract][Full Text] [Related]
22. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
[TBL] [Abstract][Full Text] [Related]
23. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy.
Boughey JC; Cormier JN; Xing Y; Hunt KK; Meric-Bernstam F; Babiera GV; Ross MI; Kuerer HM; Singletary SE; Bedrosian I
Cancer; 2007 Dec; 110(11):2542-50. PubMed ID: 17932905
[TBL] [Abstract][Full Text] [Related]
24. Eighteen sensations after breast cancer surgery: a two-year comparison of sentinel lymph node biopsy and axillary lymph node dissection.
Baron RH; Fey JV; Borgen PI; Van Zee KJ
Oncol Nurs Forum; 2004 Jul; 31(4):691-8. PubMed ID: 15252425
[TBL] [Abstract][Full Text] [Related]
25. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
27. Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies.
Takei H; Kurosumi M; Yoshida T; Ishikawa Y; Hayashi Y; Ninomiya J; Tozuka K; Oba H; Inoue K; Nagai S; Saito Y; Kazumoto T; Saitoh J; Tabei T
Breast Cancer; 2010; 17(1):9-16. PubMed ID: 19701679
[TBL] [Abstract][Full Text] [Related]
28. Eighteen sensations after breast cancer surgery: a 5-year comparison of sentinel lymph node biopsy and axillary lymph node dissection.
Baron RH; Fey JV; Borgen PI; Stempel MM; Hardick KR; Van Zee KJ
Ann Surg Oncol; 2007 May; 14(5):1653-61. PubMed ID: 17295084
[TBL] [Abstract][Full Text] [Related]
29. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
30. Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma.
Langer S; Guenther JM; Haigh PI; Difronzo LA
Am Surg; 2004 Oct; 70(10):881-5. PubMed ID: 15529842
[TBL] [Abstract][Full Text] [Related]
31. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.
Petrik DW; McCready DR; Sawka CA; Goel V
J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062
[TBL] [Abstract][Full Text] [Related]
32. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
33. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
[TBL] [Abstract][Full Text] [Related]
34. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
35. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.
Del Bianco P; Zavagno G; Burelli P; Scalco G; Barutta L; Carraro P; Pietrarota P; Meneghini G; Morbin T; Tacchetti G; Pecoraro P; Belardinelli V; De Salvo GL;
Eur J Surg Oncol; 2008 May; 34(5):508-13. PubMed ID: 17614245
[TBL] [Abstract][Full Text] [Related]
36. Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer.
Wasif N; Maggard MA; Ko CY; Giuliano AE
Arch Surg; 2010 Feb; 145(2):161-6. PubMed ID: 20157084
[TBL] [Abstract][Full Text] [Related]
37. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.
Domènech A; Benitez A; Bajén MT; Pla MJ; Gil M; Martín-Comín J
Oncology; 2007; 72(1-2):27-32. PubMed ID: 17998787
[TBL] [Abstract][Full Text] [Related]
38. When is a lymph node dissection a lymph node dissection? The number of lymph nodes resected in sentinel and axillary lymph node dissections.
Olaya W; Wong J; Wong J; Morgan J; Kazanjian K; Lum S
Ann Surg Oncol; 2013 Feb; 20(2):627-32. PubMed ID: 22956069
[TBL] [Abstract][Full Text] [Related]
39. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.
Rietman JS; Dijkstra PU; Geertzen JH; Baas P; de Vries J; Dolsma WV; Groothoff JW; Eisma WH; Hoekstra HJ
Ann Surg Oncol; 2004 Nov; 11(11):1018-24. PubMed ID: 15525832
[TBL] [Abstract][Full Text] [Related]
40. Is axillary dissection needed in node-positive breast cancer?
Greenberg CC; Bafford AC; Golshan M
Expert Rev Anticancer Ther; 2008 Feb; 8(2):195-8. PubMed ID: 18279060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
